Citi Pharma gets CCP Nod for 100% acquisition of Pakheim International Pharma
Mettis Global • • 1 min read
Mettis Link News reported that the Competition Commission of Pakistan has authorised Citi Pharma Limited (PSX: CPHL) to acquire the entire shareholding of Pakheim International Pharma (Private) Limited. The pharmaceutical company disclosed the approval through a PSX filing, citing an order dated October 9, 2026, issued under Case No. 1614/Merger-CCP/2026.
After its review, the CCP judged that the deal poses no competition problems, clearing the way for the authorisation. The acquisition will proceed under the share purchase agreement of May 6, 2026, once all outstanding legal, regulatory and other steps are finished.
For PSX investors, the filing confirms that the competition hurdle has been cleared, while completion still depends on the remaining legal and regulatory steps. The approval is therefore a milestone in a transaction that was agreed earlier in the year.
At a glance
- The CCP authorised Citi Pharma's proposed acquisition of 100% of Pakheim International Pharma.
- The CCP determined the deal raises no competition concerns.
- Completion depends on the share purchase agreement and remaining legal and regulatory formalities.
Stocks in this story
Originally reported by Mettis Global
This page is Investify's own summary. The full report, with all details and context, is on the publisher's site.
Read the full storyWant the full article here?
Log in to read the full article in the Investify reader, in English or Urdu.
Investify summarizes Pakistan Stock Exchange news in its own words and links each story to its original publisher. We always credit the source so you can read the full report and verify the details before making financial decisions.
More on CPHL
CCP allows Citi Pharma to acquire PakheimBR• 20 Oct 2026Neutral coverage
Citi Pharma secures CCP approval to acquire 100% stake in Pakheim International PharmaProfit• 19 Oct 2026Positive coverage
Citi Pharma receives CCP nod to acquire Pakheim InternationalBR• 19 Oct 2026Positive coverage- CPHL FY26 profit softens 11%Mettis• 5 Oct 2026Negative coverage
- Citi Pharma gets shareholder nod to alter memorandum for cannabis businessMettis• 18 Sept 2026Neutral coverage
Uploading order to FBR’s IRIS portal alone not valid delivery, rules LHCDawn• 30 Oct 2026
